Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis

Osteoporosis International

Volumn 20, Issue 11, 2009, Pages 1895-1902

  Kendler, D L ^a   Ringe, J D ^b   Ste Marie, L G ^c   Vrijens, B ^d   Taylor, E B ^e   Delmas, P D ^f  

^a Environmental Health Services   (Canada)

^b KLINIKUM LEVERKUSEN   (Germany)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d AARDEX Group   (Switzerland)

^e PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^f UNIVERSITÉ LYON 1   (France)

Author keywords

Flexible dosing; Osteoporosis; Risedronate; Treatment regimen

Indexed keywords

RISEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; GEOGRAPHIC DISTRIBUTION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONVERTEBRAL FRACTURE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; SINGLE-BLIND METHOD;

EID: 76449110191     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0893-2     Document Type: Article

References (14)

1. NH Miller 1997 Compliance with treatment regimens in chronic asymptomatic diseases Am J Med 102 43 49 10.1016/S0002-9343(97)00467-1 9217586 1:STN:280:DyaK2szmtVKhsA%3D%3D (Pubitemid 27147947)
2. JS McCombs P Thiebaud C McLaughlin-Miley, et al. 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis Maturitas 48 271 287 10.1016/j.maturitas.2004.02.005 15207894 1:CAS:528:DC%2BD2cXltVCiu7g%3D (Pubitemid 38781153)
3. L Osterberg T Blaschke 2005 Adherence to medication N Engl J Med 353 487 497 10.1056/NEJMra050100 16079372 1:CAS:528:DC%2BD2MXntVCisL0%3D (Pubitemid 41127293)
4. B Clemmesen P Ravn B Zegels, et al. 1997 A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis Osteoporos Int 7 488 495 10.1007/PL00004152 9425508 1:STN:280: DyaK1c%2Fos1Kntw%3D%3D (Pubitemid 27443076)
5. L Mortensen P Charles PJ Bekker, et al. 1998 Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up J Clin Endocrinol Metab 83 396 402 10.1210/jc.83.2.396 9467547 1:CAS:528:DyaK1cXhtVSmsro%3D (Pubitemid 28496512)
6. ST Harris NB Watts HK Genant, et al. 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group JAMA 282 1344 1352 10.1001/jama.282.14.1344 10527181 1:CAS:528:DyaK1MXmvFansr0%3D (Pubitemid 29483192)
7. JY Reginster HW Minne OH Sörenson on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group, et al. 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporos Int 11 83 91 10.1007/s001980050010 10663363 1:CAS:528:DC%2BD3cXhvFGgsr0%3D (Pubitemid 30099515)
8. DY Mitchell MA Heise KA Pallone, et al. 1999 The effect of dosing regimen on the pharmacokinetics of risedronate Br J Clin Pharmacol 48 536 542 10.1046/j.1365-2125.1999.00035.x 10583024 1:CAS:528:DyaK1MXmvFaksr4%3D (Pubitemid 29454234)
9. Vrijens B, van de Langerijt L, Watts NB, et al (2003) Electronic monitoring of adherence to therapy in postmenopausal osteoporosis: the IMPACT study. Proceedings of the 30th European Symposium on Calcified Tissues, May 8-9
10. PD Delmas B Vrijens R Eastell on behalf of the Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators, et al. 2007 Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis J Clin Endocrinol Metab 92 1296 1304 10.1210/jc.2006-1526 17244788 1:CAS:528:DC%2BD2sXksVSrsbc%3D (Pubitemid 46556401)
11. SJ Phillips 2000 FDA reform legislation and its effect on clinical trials ASAIO J 46 19 20 10.1097/00002480-200001000-00006 10667708 1:STN:280: DC%2BD3c7ivFWksg%3D%3D
12. NB Watts C Cooper R Lindsay, et al. 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 261 10.1385/JCD:7:3:255 15319494 (Pubitemid 39178892)
13. S Agrawal DC Krueger JA Engelke, et al. 2006 Between-meal risedronate does not alter bone turnover in nursing home residents J Am Geriatr Soc 54 790 795 10.1111/j.1532-5415.2006.00696.x 16696745 (Pubitemid 44030201)
14. D Hosking S Adami D Felsenberg, et al. 2003 Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study Curr Med Res Opin 19 383 394 10.1185/030079903125002009 13678475 1:CAS:528:DC%2BD3sXnsVGitrY%3D (Pubitemid 37006371)